|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.4500 - 0.5500|
|52 Week Range||0.4220 - 2.2500|
|Beta (3Y Monthly)||4.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biotricity Inc. (OTCQB: BTCY), today announced that its CEO and Founder Waqaas Al-Siddiq will be on The Claman Countdown airing on Fox Business Network (FBN) on Wednesday, September 11th at 3:15 PM EDT. Mr. Al-Siddiq will discuss the current economic climate and how the Chinese tariff affects small and growing medical device companies, and ultimately, US patients.
After achieving FDA clearance, the Company’s first remote patient monitoring (RPM) solution, Bioflux, experienced a high adoption rate during its fiscal 2018 limited market release to anchor clinics. In the first three months of fiscal year 2019, the Company has transitioned to full US release, ramping up its small sales force and expanding its sales footprint to 11 key states, with plans to expand further. This shift has the potential to improve patient care and save additional lives while also saving significant healthcare costs.
Two digital health officials told Yahoo Finance recently that Medicare for All could help address some of the industry’s toughest challenges.
Biotricity Inc. (OTCQB: BTCY), today announced that its CEO and Founder Waqaas Al-Siddiq will be on Yahoo Finance’s On the Move show on Tuesday, August 20th, airing at 11:45 AM EDT. Mr. Al-Siddiq will discuss American healthcare coverage and how insurance plans, whether public or private, impact growing, start-up medical device companies. Currently, more than seven million patients benefit from remote monitoring and the use of connected medical devices, and nearly 1,800 hospitals in the US are using mobile applications to improve risk management and care quality.
Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has completed its 10-K filing for the fiscal year, which ended March 31, 2019. The increase in revenues reaffirms the Company’s positive commercialization progress. Increased Market Penetration: Without including future new device placements, revenue run rates for Biotricity’s current installed customer base are projected to deliver over $2 million in recurring technology fees over the next 12 months.
Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has expanded its fleet of Bioflux devices to meet customer demand. “Our sales expansion is yielding results and we see a consistent increase in sales as a result of our anchor clients recommending us to other medical professionals,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. Long-term, we are a technology company with a pipeline of complimentary remote patient monitoring and pre-emptive diagnostic technologies that will allow us to leapfrog and build on our existing platform.
Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today provided a progress report for its fiscal 2018 fourth quarter, which ended March 31, 2019. The company continues to execute its plans to grow its sales force, expand its geographic footprint, and reach more Americans with its life-saving technology. The company’s flagship product, Bioflux, was met with a high adoption rate in the clinical community throughout the soft launch of the past year, leading to positive customer feedback and steady re-order rates.
Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, has expanded its sales team to cover two additional states in the US that are key to driving faster adoption of its flagship product, Bioflux. The Company has been experiencing great traction with its technology in the marketplace and is taking the opportunity to capitalize on its momentum and increase its regional footprint. The Company’s remote patient monitoring device Bioflux monitors a patient’s ECG in near real-time, constantly analyzing and collecting data on the device and periodically uploading to the cloud via embedded cellular technology.
Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to announce further buildout of its R&D team, with the engagement of the Biomedical Engineering Department at the University of Calgary. The expanded team will include a Biomedical Engineering (BME) fellow under Dr. Ferber, Director of Biomedical Engineering’s Human Performance Laboratory, who will explore and develop effective representations of both fetal/maternal heart rate variability (HRV) and electro-hysterography (labor contraction monitoring) in pregnancy.
Biotricity, Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today announced that it has achieved significant progress in their University of Calgary-based R & D program for their latest wellness monitoring systems. Clinical data collection has commenced for both its fetal/maternal and ambulatory adult heart rate variability (HRV) monitoring systems. Dr. David Liepert, QA/QI and Safety Lead and Director for the University of Calgary Cumming School of Medicine Department of Anesthesia commented, “We could not be more excited to participate in developing both these non-invasive medical-grade ambulatory monitors, utilizing the amazing fidelity and mobility of the Bioflux system.
Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, is providing an end of year update to its shareholders. “2018 was an exciting year for Biotricity as we launched our first medical-grade device into the growing cardiac market and received great reception from our initial sales forays,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. The Company experienced a 211% growth in sales from Q2 2018 to Q3 2018.
Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will be actively pursuing the Holter market in addition to the MCT market with its Bioflux product offering, expanding its revenue growth opportunities. Bioflux is a 3 in 1 monitoring solution, offering mobile cardiac telemetry (MCT), event, and Holter monitoring.
Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced the launch of its 2019 R&D program at the University of Calgary. The Company is initiating a series of investigations using the 1000 Hz fidelity of Bioflux to facilitate ambulatory Heart Rate Variability (HRV) monitoring for maternity and in both major and emergency surgery patients at Rockyview General Hospital in Calgary. Successful results will open up two growing remote monitoring (RPM) markets for Biotricity’s technology: maternal and post-operative remote monitoring.
A major shift in healthcare could rival this new industry as the biggest health insurer in the U.S., Medicare & Medicaid, tries to save money by moving more procedures (and patients) out of hospitals into smaller surgical centers and get them out of the surgical setting rapidly. Medicare is already saving billions each year according to a recent study and is hoping to save almost $60 billion in the coming years through this huge cost cutting measure. Remote patient monitoring, already a big and lucrative business, is likely to become a whole lot larger.
Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that Drs. Donald S. (Buck) Cross, Edward Lazaga, Imran Mohiuddin, Radoslaw (Stefan) Kiesz, and Tea Acuff will be joining the Company’s Scientific and Medical Alliance Board. “We are fortunate to add such high caliber physicians to our Scientific and Medical Alliance Board,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. The Company is leveraging the success of its RPM platform within Bioflux and applying it in remote patient monitoring solutions for a wide array of chronic conditions that will help aid disease management and improve patient engagement.